ABVC BioPharma (ABVC) Revenue & Revenue Breakdown
ABVC BioPharma Revenue Highlights
Latest Revenue (Y)
$152.43K
Latest Revenue (Q)
$117.14K
ABVC BioPharma Revenue by Period
ABVC BioPharma Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $152.43K | -84.28% |
| 2022-12-31 | $969.78K | 172.57% |
| 2021-12-31 | $355.80K | -26.34% |
| 2020-12-31 | $483.05K | -31.16% |
| 2019-12-31 | $701.72K | 9987.97% |
| 2018-12-31 | $6.96K | 117.65% |
| 2017-12-31 | $3.20K | 9887.50% |
| 2016-09-30 | $32.00 | -99.05% |
| 2015-09-30 | $3.36K | 100.00% |
| 2014-09-30 | - | -100.00% |
| 2013-09-30 | $7.79K | 36.28% |
| 2012-09-30 | $5.71K | 79.12% |
| 2011-09-30 | $3.19K | -78.53% |
| 2010-09-30 | $14.86K | 100.00% |
| 2009-09-30 | - | -100.00% |
| 2008-09-30 | $25.09K | -39.78% |
| 2007-09-30 | $41.67K | 100.00% |
| 2006-12-31 | - | 100.00% |
| 2005-12-31 | - | -100.00% |
| 2004-12-31 | $57.49K | 320.59% |
| 2003-12-31 | $13.67K | 36.70% |
| 2002-12-31 | $10.00K | - |
ABVC BioPharma generated $152.43K in revenue during NA 2023, up -84.28% compared to the previous quarter, and up 2191.35% compared to the same period a year ago.
ABVC BioPharma Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $117.14K | 9621.33% |
| 2024-03-31 | $1.21K | -44.34% |
| 2023-12-31 | $2.17K | -86.37% |
| 2023-09-30 | $15.88K | 160.01% |
| 2023-06-30 | $6.11K | -95.24% |
| 2023-03-31 | $128.27K | -78.22% |
| 2022-12-31 | $588.99K | 1293.44% |
| 2022-09-30 | $42.27K | -86.49% |
| 2022-06-30 | $312.86K | 1119.25% |
| 2022-03-31 | $25.66K | -167.90% |
| 2021-12-31 | $-37.79K | -138.18% |
| 2021-09-30 | $99.00K | 214.87% |
| 2021-06-30 | $31.44K | -88.05% |
| 2021-03-31 | $263.15K | 323.12% |
| 2020-12-31 | $62.19K | -46.18% |
| 2020-09-30 | $115.55K | -48.99% |
| 2020-06-30 | $226.51K | 187.50% |
| 2020-03-31 | $78.79K | -21.18% |
| 2019-12-31 | $99.96K | -49.45% |
| 2019-09-30 | $197.73K | 3.10% |
| 2019-06-30 | $191.78K | -9.64% |
| 2019-03-31 | $212.24K | 7022.21% |
| 2018-12-31 | $2.98K | 298.93% |
| 2018-09-30 | $747.00 | -76.87% |
| 2018-06-30 | $3.23K | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | -100.00% |
| 2016-12-31 | $70.00K | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | -100.00% |
| 2016-03-31 | $32.00 | 100.00% |
| 2015-12-31 | - | -100.00% |
| 2015-09-30 | $1.10K | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | -100.00% |
| 2013-03-31 | $761.00 | -89.17% |
| 2012-12-31 | $7.03K | 100.00% |
| 2012-09-30 | - | 100.00% |
| 2012-05-14 | - | -100.00% |
| 2012-02-20 | $3.67K | 78.87% |
| 2011-12-15 | $2.05K | 100.00% |
| 2011-08-03 | - | 100.00% |
| 2011-06-30 | - | -100.00% |
| 2011-02-13 | $720.00 | -70.85% |
| 2011-01-12 | $2.47K | 115.53% |
| 2010-08-15 | $1.15K | -59.49% |
| 2010-06-30 | $2.83K | -47.88% |
| 2010-03-31 | $5.43K | 100.00% |
| 2009-09-30 | - | 100.00% |
| 2009-06-30 | - | 100.00% |
| 2009-03-31 | - | -100.00% |
| 2008-12-31 | $5.46K | 2523.56% |
| 2008-09-30 | $208.00 | -94.86% |
| 2008-06-30 | $4.05K | -61.12% |
| 2008-03-31 | $10.42K | - |
ABVC BioPharma generated $117.14K in revenue during Q2 2024, up 9621.33% compared to the previous quarter, and up 91.32% compared to the same period a year ago.
ABVC BioPharma Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| SABS | SAB Biotherapeutics | $2.24M | $263.14K |
| NTRB | Nutriband | $2.09M | $408.53K |
| LGVN | Longeveron | $709.00K | $548.00K |
| ADTX | Aditxt | $645.18K | $44.28K |
| MGTA | Dianthus Therapeutics | $314.00K | $72.00K |
| ABVC | ABVC BioPharma | $152.43K | $117.14K |
| VRAX | Virax Biolabs Group | $8.56K | $76.50K |
| ANEB | Anebulo Pharmaceuticals | - | - |
| APTX | Aptinyx | - | - |
| FBRX | Forte Biosciences | - | - |
| EVLO | Evelo Biosciences | - | - |
| ALRN | Aileron Therapeutics | - | - |
| AKTX | Akari Therapeutics | - | - |
| ARDS | Aridis Pharmaceuticals | - | $417.00K |
| RNXT | RenovoRx | - | - |
| MNPR | Monopar Therapeutics | - | - |
| INDP | Indaptus Therapeutics | - | - |
| QNRX | Quoin Pharmaceuticals | - | - |
| ELDN | Eledon Pharmaceuticals | - | - |
| KTTA | Pasithea Therapeutics | - | - |
| ACST | Acasti Pharma | - | - |
ABVC Revenue FAQ
What is ABVC BioPharma’s yearly revenue?
ABVC BioPharma's yearly revenue for 2023 was $152.43K, representing a decrease of -84.28% compared to 2022. The company's yearly revenue for 2022 was $969.78K, representing an increase of 172.57% compared to 2021. ABVC's yearly revenue for 2021 was $355.8K, representing a decrease of -26.34% compared to 2020.
What is ABVC BioPharma’s quarterly revenue?
ABVC BioPharma's quarterly revenue for Q2 2024 was $117.14K, a 9621.33% increase from the previous quarter (Q1 2024), and a 1817.53% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $1.2K, a -44.34% decrease from the previous quarter (Q4 2023), and a -99.06% decrease year-over-year (Q1 2023). ABVC's quarterly revenue for Q4 2023 was $2.16K, a -86.37% decrease from the previous quarter (Q3 2023), and a -99.63% decrease year-over-year (Q4 2022).
What is ABVC BioPharma’s revenue growth rate?
ABVC BioPharma's revenue growth rate for the last 3 years (2021-2023) was -57.16%, and for the last 5 years (2019-2023) was -78.28%.